These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 19111466)

  • 21. Synthesis and modeling of new benzofuranone histone deacetylase inhibitors that stimulate tumor suppressor gene expression.
    Charrier C; Clarhaut J; Gesson JP; Estiu G; Wiest O; Roche J; Bertrand P
    J Med Chem; 2009 May; 52(9):3112-5. PubMed ID: 19385600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
    Suzuki T; Nagano Y; Kouketsu A; Matsuura A; Maruyama S; Kurotaki M; Nakagawa H; Miyata N
    J Med Chem; 2005 Feb; 48(4):1019-32. PubMed ID: 15715470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trithiocarbonates: exploration of a new head group for HDAC inhibitors.
    Dehmel F; Ciossek T; Maier T; Weinbrenner S; Schmidt B; Zoche M; Beckers T
    Bioorg Med Chem Lett; 2007 Sep; 17(17):4746-52. PubMed ID: 17606370
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
    Senger J; Melesina J; Marek M; Romier C; Oehme I; Witt O; Sippl W; Jung M
    J Med Chem; 2016 Feb; 59(4):1545-55. PubMed ID: 26653328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alkyl piperidine and piperazine hydroxamic acids as HDAC inhibitors.
    Rossi C; Porcelloni M; D'Andrea P; Fincham CI; Ettorre A; Mauro S; Squarcia A; Bigioni M; Parlani M; Nardelli F; Binaschi M; Maggi CA; Fattori D
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2305-8. PubMed ID: 21420859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of novel isoform-selective inhibitors within class I histone deacetylases.
    Hu E; Dul E; Sung CM; Chen Z; Kirkpatrick R; Zhang GF; Johanson K; Liu R; Lago A; Hofmann G; Macarron R; de los Frailes M; Perez P; Krawiec J; Winkler J; Jaye M
    J Pharmacol Exp Ther; 2003 Nov; 307(2):720-8. PubMed ID: 12975486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histone deacetylase inhibitors that target tubulin.
    Schemies J; Sippl W; Jung M
    Cancer Lett; 2009 Aug; 280(2):222-32. PubMed ID: 19268440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thiol-based SAHA analogues as potent histone deacetylase inhibitors.
    Suzuki T; Kouketsu A; Matsuura A; Kohara A; Ninomiya S; Kohda K; Miyata N
    Bioorg Med Chem Lett; 2004 Jun; 14(12):3313-7. PubMed ID: 15149697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of novel, selective, and stable inhibitors of class II histone deacetylases. Validation studies of the inhibition of the enzymatic activity of HDAC4 by small molecules as a novel approach for cancer therapy.
    Ontoria JM; Altamura S; Di Marco A; Ferrigno F; Laufer R; Muraglia E; Palumbi MC; Rowley M; Scarpelli R; Schultz-Fademrecht C; Serafini S; Steinkühler C; Jones P
    J Med Chem; 2009 Nov; 52(21):6782-9. PubMed ID: 19888759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors.
    Zhang Y; Feng J; Liu C; Zhang L; Jiao J; Fang H; Su L; Zhang X; Zhang J; Li M; Wang B; Xu W
    Bioorg Med Chem; 2010 Mar; 18(5):1761-72. PubMed ID: 20171895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trithiocarbonates as a novel class of HDAC inhibitors: SAR studies, isoenzyme selectivity, and pharmacological profiles.
    Dehmel F; Weinbrenner S; Julius H; Ciossek T; Maier T; Stengel T; Fettis K; Burkhardt C; Wieland H; Beckers T
    J Med Chem; 2008 Jul; 51(13):3985-4001. PubMed ID: 18558669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and synthesis of a potent histone deacetylase inhibitor.
    Liu T; Kapustin G; Etzkorn FA
    J Med Chem; 2007 May; 50(9):2003-6. PubMed ID: 17419603
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity.
    Chetan B; Bunha M; Jagrat M; Sinha BN; Saiko P; Graser G; Szekeres T; Raman G; Rajendran P; Moorthy D; Basu A; Jayaprakash V
    Bioorg Med Chem Lett; 2010 Jul; 20(13):3906-10. PubMed ID: 20605448
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors.
    Finnin MS; Donigian JR; Cohen A; Richon VM; Rifkind RA; Marks PA; Breslow R; Pavletich NP
    Nature; 1999 Sep; 401(6749):188-93. PubMed ID: 10490031
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structural origin of selectivity in class II-selective histone deacetylase inhibitors.
    Estiu G; Greenberg E; Harrison CB; Kwiatkowski NP; Mazitschek R; Bradner JE; Wiest O
    J Med Chem; 2008 May; 51(10):2898-906. PubMed ID: 18412327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases.
    Wang DF; Helquist P; Wiech NL; Wiest O
    J Med Chem; 2005 Nov; 48(22):6936-47. PubMed ID: 16250652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors.
    Shinji C; Maeda S; Imai K; Yoshida M; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2006 Nov; 14(22):7625-51. PubMed ID: 16877001
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Azetidinones as zinc-binding groups to design selective HDAC8 inhibitors.
    Galletti P; Quintavalla A; Ventrici C; Giannini G; Cabri W; Penco S; Gallo G; Vincenti S; Giacomini D
    ChemMedChem; 2009 Dec; 4(12):1991-2001. PubMed ID: 19821480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate.
    Suzuki T; Kouketsu A; Itoh Y; Hisakawa S; Maeda S; Yoshida M; Nakagawa H; Miyata N
    J Med Chem; 2006 Aug; 49(16):4809-12. PubMed ID: 16884291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Substrate and inhibitor specificity of class 1 and class 2 histone deacetylases.
    Hildmann C; Wegener D; Riester D; Hempel R; Schober A; Merana J; Giurato L; Guccione S; Nielsen TK; Ficner R; Schwienhorst A
    J Biotechnol; 2006 Jun; 124(1):258-70. PubMed ID: 16567013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.